NCT01658462 - Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

October 30, 2017

Conditions

Breast Cancer

Interventions

DRUG

Docetaxel

75 mg/m2 IV Day 1 / 3 weeks

DRUG

Nintedanib

"200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered"

DRUG

Docetaxel: increase of the dose

Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator

Trial Locations (12)

Hôpital Bretonneau, Tours

Institut Jean Godinot, Reims

Nouvelle Clinique des Dentellières, Valenciennes

CH Compiègne-Noyon, Compiègne

Hôpital Privé les Bonnettes, Arras

CMCO de la Côte d'Opale, Saint-Martin-Boulogne

Centre Pierre Curie, Beuvry

Polyclinique de Limoges - site Chénieux, Limoges

CHU Amiens- Hôpital Sud, Amiens

Centre Léonard de Vinci, Dechy

Centre Oscar Lambret, Lille

Centre Alexis Vautrin, Vandœuvre-lès-Nancy